Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Vaccaro, V ^a   Fabi, A ^a   Vidiri, A ^a   Giannarelli, D ^a   Metro, G ^b   Telera, S ^a   Vari, S ^a   Piludu, F ^a   Carosi, M A ^a   Villani, V ^a   Cognetti, F ^a   Pompili, A ^a   Marucci, L ^a   Carapella, C M ^a   Pace, A ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FOTEMUSTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CANCER RECURRENCE; CLINICAL ARTICLE; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG SAFETY; EPISTAXIS; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LEUKOPENIA; LIVER DISEASE; MAINTENANCE CHEMOTHERAPY; MALE; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VOMITING; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GLIOMA; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; SURVIVAL RATE;

EID: 84901753366     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/351252     Document Type: Article

References (30)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA Cancer Journal for Clinicians 2012 62 1 10 29 2-s2.0-84855792427 10.3322/caac.20138
2. Stupp R., Hegi M. E., Mason W. P., van den Bent M. J., Taphoorn M. J., Janzer R. C., Ludwin S. K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A. A., Gijtenbeek J., Marosi C., Vecht C. J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J. G., Mirimanoff R.-O., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology 2009 10 5 459 466 2-s2.0-65349121788 10.1016/S1470-2045(09)70025-7
3. Stupp R., Mason W. P., van den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 2005 352 10 987 996 2-s2.0-20044366163 10.1056/NEJMoa043330 (Pubitemid 40349501)
4. Addeo R., Caraglia M., De Santi M. S., Montella L., Abbruzzese A., Parlato C., Vincenzi B., Carraturo M., Faiola V., Genovese M., Cennamo G., Del Prete S., A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. Journal of Neuro-Oncology 2011 102 3 417 424 2-s2.0-79958208733 10.1007/s11060-010-0329-z
5. Brandes A. A., Tosoni A., Franceschi E., Blatt V., Santoro A., Faedi M., Amistà P., Gardiman M., Labianca R., Bianchini C., Ermani M., Reni M., Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology 2009 64 4 769 775 2-s2.0-68149169111 10.1007/s00280-009-0926-8
6. Fabi A., Metro G., Russillo M., Vidiri A., Carapella M. C., Maschio M., Cognetti F., Jandolo B., Mirri M., Sperduti I., Telera S., Carosi M., Pace A., Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. BMC Cancer 2009 9, article 101 2-s2.0-65349095669 10.1186/1471-2407-9-101
7. Fabi A., Metro G., Vidiri A., Lanzetta G., Carosi M., Telera S., Maschio M., Russillo M., Sperduti I., Carapella C. M., Cognetti F., Pace A., Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. Journal of Neuro-Oncology 2010 100 2 209 215 2-s2.0-79952194350 10.1007/s11060-010-0163-3
8. Khayat D., Giroux B., Berille J., Cour V., Gerard B., Sarkany M., Bertrand P., Bizzari J.-P., Fotemustine in the treatment of brain primary tumors and metastases. Cancer Investigation 1994 12 4 414 420 2-s2.0-0028026654 (Pubitemid 24261299)
9. Nghiemphu P. L., Liu W., Lee Y., Than T., Graham C., Lai A., Green R. M., Pope W. B., Liau L. M., Mischel P. S., Nelson S. F., Elashoff R., Cloughesy T. F., Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009 72 14 1217 1222 2-s2.0-65249185501 10.1212/01.wnl.0000345668.03039.90
10. Chamberlain M. C., Bevacizumab for the treatment of recurrent glioblastoma. Clinical Medicine Insights: Oncology 2011 5 117 129 2-s2.0-79958031331 10.4137/CMO.S7232
11. Desjardins A., Reardon D. A., Herndon J. E. II, Marcello J., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Sampson J., Bailey L., Bigner D. D., Friedman A. H., Friedman H. S., Vredenburgh J. J., Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research 2008 14 21 7068 7073 2-s2.0-58149231546 10.1158/1078-0432.CCR-08-0260
12. Friedman H. S., Prados M. D., Wen P. Y., Mikkelsen T., Schiff D., Abrey L. E., Yung W. K. A., Paleologos N., Nicholas M. K., Jensen R., Vredenburgh J., Huang J., Zheng M., Cloughesy T., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology 2009 27 28 4733 4740 2-s2.0-70350461699 10.1200/JCO.2008.19.8721
13. Raizer J. J., Grimm S., Chamberlain M. C., Nicholas M. K., Chandler J. P., Muro K., Dubner S., Rademaker A. W., Renfrow J., Bredel M., A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010 116 22 5297 5305 2-s2.0-78449274656 10.1002/cncr.25462
14. Chamberlain M. C., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2009 72 8 772 774 2-s2.0-62349110751 10.1212/01.wnl.0000339387.03225.0a
15. Vredenburgh J. J., Desjardins A., Herndon J. E. II, Dowell J. M., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Wagner M., Bigner D. D., Friedman A. H., Friedman H. S., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research 2007 13 4 1253 1259 2-s2.0-33947191055 10.1158/1078-0432.CCR-06-2309 (Pubitemid 46424067)
16. Vredenburgh J. J., Desjardins A., Herndon J. E. II, Marcello J., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D. D., Friedman A. H., Friedman H. S., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology 2007 25 30 4722 4729 2-s2.0-36049037819 10.1200/JCO.2007.12.2440 (Pubitemid 350086473)
17. Wen P. Y., Macdonald D. R., Reardon D. A., Cloughesy T. F., Sorensen A. G., Galanis E., DeGroot J., Wick W., Gilbert M. R., Lassman A. B., Tsien C., Mikkelsen T., Wong E. T., Chamberlain M. C., Stupp R., Lamborn K. R., Vogelbaum M. A., Van Den Bent M. J., Chang S. M., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of Clinical Oncology 2010 28 11 1963 1972 2-s2.0-77951625266 10.1200/JCO.2009.26.3541
18. A'Hern R. P., Sample size tables for exact single-stage phase II designs. Statistics in Medicine 2001 20 6 859 866 2-s2.0-0035970795 10.1002/sim.721 (Pubitemid 32249085)
19. Norden A. D., Young G. S., Setayesh K., Muzikansky A., Klufas R., Ross G. L., Ciampa A. S., Ebbeling L. G., Levy B., Drappatz J., Kesari S., Wen P. Y., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008 70 10 779 787 2-s2.0-41649112610 10.1212/01.wnl.0000304121.57857.38
20. Gilbert M. R., Wang M., Aldape K., RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). Journal of Clinical Oncology 2009 27 supplement 15. ASCO Meeting Abstracts, abstract: 2011
21. Chamberlain M. C., Johnston S. K., Salvage therapy with single agent bevacizumab for recurrent glioblastoma. Journal of Neuro-Oncology 2010 96 2 259 269 2-s2.0-75049085069 10.1007/s11060-009-9957-6
22. Kreisl T. N., Kim L., Moore K., Duic P., Royce C., Stroud I., Garren N., Mackey M., Butman J. A., Camphausen K., Park J., Albert P. S., Fine H. A., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology 2009 27 5 740 745 2-s2.0-59949083263 10.1200/JCO.2008.16.3055
23. Chamberlain M. C., Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010 116 17 3988 3999 2-s2.0-77956822655 10.1002/cncr.25256
24. Fabrini M. G., Silvano G., Lolli I., Perrone F., Marsella A., Scotti V., Cionini L., A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. Journal of Neuro-Oncology 2009 92 1 79 86 2-s2.0-59349113568 10.1007/s11060-008-9739-6
25. Scoccianti S., Detti B., Sardaro A., Iannalfi A., Meattini I., Leonulli B. G., Borghesi S., Martinelli F., Bordi L., Ammannati F., Biti G., Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anti-Cancer Drugs 2008 19 6 613 620 2-s2.0-53749090062 10.1097/CAD.0b013e3283005075
26. Soffietti R., Trevisan E., Bertero L., Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). Journal of Neuro-Oncology 2014 116 533 541
27. Taal W., Oosterkamp H. M., Walenkamp A. M. E., A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB Study. Journal of Clinical Oncology 2013 31, supplement. ASCO Meeting Abstracts, abstract: 2001
28. Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM). NCT01067469, http://clinicaltrials.gov/ct2/show/NCT01067469
29. Bevacizumab and Lomustine in Treating Patients with Glioblastoma Multiforme in First Recurrence. NCT01290939, http://clinicaltrials.gov/show/ NCT01290939
30. A Study of Avastin (Bevacizumab) and Fotemustine in Patients with Recurrent Glioblastoma. NCT01474239, http://clinicaltrials.gov/show/NCT01474239